CTOs on the Move

Zenabis Global

www.zenabis.com

 
Zenabis is a significant Licensed Producer of medical and recreational cannabis, and employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta and Langley, British Columbia; and Stellarton, Nova Scotia.
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Zenabis Global raised $20.8M on 11/28/2019

Similar Companies

Innovative Health

HEALTHCARE NEEDS NEW ANSWERS Hospitals in the US are financially fragile and the pandemic has brought many to the verge of bankruptcy. Meanwhile, advancements in pharmaceuticals and medical technology carry the promise of better patient care – a...

DrugSense

DrugSense is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Natrol subsidiary of Plethico Pharmaceuticals Limited

Natrol, Inc. subsidiary of Plethico Pharmaceuticals Limited is a Chatsworth, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oregon Freeze Dry

Oregon Freeze Dry, Inc. has a firm policy to produce only high quality food products in the cleanest, most modern food processing plant. Our facilities are USDA and FDA approved and are continuously inspected. We use the highest quality meat, poultry,

Deciphera

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for patients with cancer by enhancing the quality, rate and/or durability of their responses to treatment.